Comparative Pharmacology
Head-to-head clinical analysis: ALTAVERA versus NYLIA 7 7 7.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALTAVERA versus NYLIA 7 7 7.
ALTAVERA vs NYLIA 7/7/7
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of ethinyl estradiol and desogestrel: ethinyl estradiol suppresses gonadotropin release, inhibiting ovulation; desogestrel (progestin) causes cervical mucus thickening and endometrial atrophy, preventing implantation.
Combination of ethinyl estradiol and norethindrone; suppresses gonadotropin release, inhibiting ovulation and altering cervical mucus and endometrial lining.
1 tablet (ethinyl estradiol 0.03 mg / levonorgestrel 0.15 mg) orally once daily for 21 days, followed by 7 placebo days.
One tablet orally once daily, with each tablet containing 0.035 mg ethinyl estradiol and sequentially 0.5 mg, 0.75 mg, 1 mg norgestimate for days 1-7, 8-14, 15-21 respectively, followed by 7 placebo days.
None Documented
None Documented
Levonorgestrel: terminal elimination half-life 25±10 hours; ethinyl estradiol: 13±7 hours. Clinical context: steady-state concentrations achieved within 5-7 days; contraceptive efficacy requires consistent daily dosing.
Terminal elimination half-life is 14 hours (range 10–18 hours). In renal impairment (CrCl <30 mL/min), half-life extends to 30–50 hours, necessitating dose adjustment.
Renal excretion of metabolites and unchanged drug: ~30% (levonorgestrel) and ~20% (ethinyl estradiol) in urine; biliary/fecal elimination: ~40-50% as conjugates and metabolites.
Renal (70% as unchanged drug, 10% as active metabolite), fecal (15%), biliary (5%)
Category C
Category C
Combined Oral Contraceptive
Combined Oral Contraceptive